Nasdaq

Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and ...

Daré to receive $1 million in July 2023 and $181.8 million in potential milestone payments from Organon under XACIATO global license agreement SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Daré ...
Nasdaq

Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and ...

Title: The DARE to PLAY™ Difference Date: Monday, November 17, 2025Time: 12:00pm ETRegistration and Access: https://cvent.me/KO1obd DARE to PLAY™ Sildenafil Cream is a first-of-its-kind topical ...
Yahoo Finance

Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and ...

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reaffirmed its commitment to the commercial launch of XACIATO ...
Yahoo Finance

Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and ...

DARE to PLAY™ Sildenafil Cream is a first-of-its-kind topical sildenafil formulation designed specifically for women to enhance genital blood flow and arousal response. Supported by clinical data ...